Update Breast Cancer 2022 Part 5 – Early Stage Breast Cancer

Fehm TN, Welslau M, Müller V, Lüftner D, Schütz F, Fasching P, Janni W, Thomssen C, Witzel I, Beierlein M, Belleville E, Untch M, Thill M, Tesch H, Ditsch N, Lux MP, Aktas B, Banys-Paluchowski M, Kolberg-Liedtke C, Hartkopf AD, Wöckel A, Kolberg HC, Harbeck N, Stickeler E (2023)


Publication Type: Journal article, Review article

Publication year: 2023

Journal

Book Volume: 83

Pages Range: 289-298

Journal Issue: 3

DOI: 10.1055/a-2018-9053

Abstract

The treatment of patients with early stage breast cancer has changed in recent years due to the introduction of pembrolizumab, olaparib, and abemaciclib. These and other drugs with the same class of active ingredient are currently in trial for various indications. This review article summarizes the latest results that have either been presented at major conferences such as the ESMO 2022 or published recently in international journals. This includes reports on newly discovered breast cancer genes, atezolizumab in neoadjuvant therapy in HER2-positive patients, long-term data from the APHINITY study, and on how preoperative peritumoral application of local anesthetics can influence the prognosis. We also present solid data on dynamic Ki-67 from the ADAPT studies.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Fehm, T.N., Welslau, M., Müller, V., Lüftner, D., Schütz, F., Fasching, P.,... Stickeler, E. (2023). Update Breast Cancer 2022 Part 5 – Early Stage Breast Cancer. Geburtshilfe und Frauenheilkunde, 83(3), 289-298. https://doi.org/10.1055/a-2018-9053

MLA:

Fehm, Tanja N., et al. "Update Breast Cancer 2022 Part 5 – Early Stage Breast Cancer." Geburtshilfe und Frauenheilkunde 83.3 (2023): 289-298.

BibTeX: Download